Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Harrison

Showing results (61-70 of 318) with videos related to

Pageof 32
Sort By:
Gastroenterology|November 25, 2021
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic SteatohepatitisRohit Loomba, Vlad Ratziu, Stephen A Harrison, et al.
Drugs|November 12, 2003
Advances in the understanding and treatment of nonalcoholic fatty liver diseaseStephen A Harrison, Adrian M Di Bisceglie
Hepatology (Baltimore, Md.)|April 12, 2011
Insulin sensitizers in nonalcoholic steatohepatitisStephen A Harrison, Steven Schenker, Kenneth Cusi
Journal of Hepatology|November 12, 2022
MEFIB vs. MAST and FAST: Not a competition but useful toolsMazen Noureddin, Stephen A Harrison, Naim Alkhouri
Gut|January 22, 2011
Insulin resistance and hepatitis C: an evolving storyMohammed Eslam, Mahmoud Aboelneen Khattab, Stephen A Harrison
Gut|October 28, 2021
Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?Michael Pavlides, Ferenc E Mózes, Stephen A Harrison
The American Journal of Gastroenterology|August 28, 2004
The role of vitamin E and C therapy in NASHStephen A Harrison, John A Ward, Steven Schenker
Clinics in Liver Disease|November 27, 2013
Nutrition in cirrhosis and chronic liver diseaseWassem Juakiem, Dawn M Torres, Stephen A Harrison
The American Journal of Gastroenterology|September 23, 2003
The natural history of nonalcoholic fatty liver disease: a clinical histopathological studyStephen A Harrison, Sigurd Torgerson, Paul H Hayashi
Journal of Clinical Gastroenterology|October 21, 2011
Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old manStephen J Park, Nadege Gunn, Stephen A Harrison
Pageof 32

Showing results (61-70 of 318) with videos related to

Sort By:
Pageof 32
Gastroenterology|November 25, 2021
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic SteatohepatitisRohit Loomba, Vlad Ratziu, Stephen A Harrison, et al.
Drugs|November 12, 2003
Advances in the understanding and treatment of nonalcoholic fatty liver diseaseStephen A Harrison, Adrian M Di Bisceglie
Hepatology (Baltimore, Md.)|April 12, 2011
Insulin sensitizers in nonalcoholic steatohepatitisStephen A Harrison, Steven Schenker, Kenneth Cusi
Journal of Hepatology|November 12, 2022
MEFIB vs. MAST and FAST: Not a competition but useful toolsMazen Noureddin, Stephen A Harrison, Naim Alkhouri
Gut|January 22, 2011
Insulin resistance and hepatitis C: an evolving storyMohammed Eslam, Mahmoud Aboelneen Khattab, Stephen A Harrison
Gut|October 28, 2021
Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?Michael Pavlides, Ferenc E Mózes, Stephen A Harrison
The American Journal of Gastroenterology|August 28, 2004
The role of vitamin E and C therapy in NASHStephen A Harrison, John A Ward, Steven Schenker
Clinics in Liver Disease|November 27, 2013
Nutrition in cirrhosis and chronic liver diseaseWassem Juakiem, Dawn M Torres, Stephen A Harrison
The American Journal of Gastroenterology|September 23, 2003
The natural history of nonalcoholic fatty liver disease: a clinical histopathological studyStephen A Harrison, Sigurd Torgerson, Paul H Hayashi
Journal of Clinical Gastroenterology|October 21, 2011
Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old manStephen J Park, Nadege Gunn, Stephen A Harrison
Pageof 32